View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Amgen Inc. - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc.: Near-term focus on pipeline execution, integration of Hori...

Our credit view of this issuer reflects its high profit margins and strong cash flow, constrained by unresolved IRS tax disputes

Moody's announces completion of a periodic review of ratings of Amgen ...

Moody's Ratings has completed a periodic review of the ratings of Amgen Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 7 March 2024 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant...

Amgen Inc. - September 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc.: Key facts and statistics - LTM June 2023

A summary company profile, detailing Amgen Inc’s business operations and financial highlights.

Amgen Inc. - June 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc.: Steady performance continues while pending Horizon acquisi...

Our credit view of this issuer reflects its high profit margins and strong cash flow, constrained by higher financial leverage associated with the pending Horizon acquisition.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Amgen Inc. - March 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-tShort Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report...

Moody's: Amgen's and Horizon Therapeutics' ratings unaffected by FTC r...

Moody's Investors Service (Moody's) commented that the ratings and outlooks of Amgen Inc. ("Amgen") and Horizon Therapeutics USA Ltd, a subsidiary of Horizon Therapeutics plc (collectively "Horizon") are unaffected by the announcement that the US Federal Trade Commission is seeking to block Amgen's ...

Amgen Inc. - December 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Brian Moretta ... (+4)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall
  • Riccardo Bindi

Hardman & Co Monthly: April 2023

Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...

AMGN AMGEN INC.
INCY INCYTE CORP
IPN IPSEN SA
NOVN NOVARTIS AG
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
REGN REGENERON PHARMACEUTICALS INC.
LLY MERCK & CO. INC.
JNJ ELI LILLY AND COMPANY
J7Z JOHNSON & JOHNSON
HZNP JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
GILD HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
BMY GILEAD SCIENCES INC.
BIIB BRISTOL-MYERS SQUIBB COMPANY
FEV BIOGEN INC.
IBT FIDELITY EUROPEAN VALUES PLC
FCSS INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FSV FIDELITY CHINA SPECIAL SITUATIONS PLC
FJV FIDELITY SPECIAL VALUES PLC
FAS FIDELITY JAPAN TRUST
AVO FIDELITY ASIAN VALUES PLC
CLIG ADVANCED ONCOTHERAPY
MRK CITY OF LONDON INVESTMENT GROUP
NOVO B MERCK KGAA
novob NOVO NORDISK A/S CLASS B
RECI NOVO NORDISK
SAN REAL ESTATE CREDIT INVESTMENTS
UCB SANOFI
HIK UCB S.A.
PIN HIKMA PHARMACEUTICALS PLC
PFIZER PANTHEON INTERNATIONAL
4506 PFIZER
4523 SUMITOMO DAINIPPON PHARMA CO. LTD.
4507 EISAI CO. LTD.
4568 SHIONOGI & CO. LTD.
VTAS DAIICHI SANKYO COMPANY LIMITED
STX VOLTA FINANCE (GBP)
4502 SHIELD THERAPEUTICS
HAT TAKEDA PHARMACEUTICAL CO. LTD.
OCI H&T GROUP
4578 OAKLEY CAPITAL INVESTMENTS
APAX OTSUKA HOLDINGS CO. LTD.
4503 APAX GLOBAL ALPHA
ICGT ASTELLAS PHARMA INC.
UTHR ICG ENTERPRISE TRUST
PFE UNITED THERAPEUTICS CORPORATION
AZN PFIZER INC.
GLAXO ASTRAZENECA PLC
ABBV GLAXOSMITHKLINE PHARMACEUTICALS
VRX CN ASTELLAS PHARMA INC
MRNA ABBVIE INC.
TXG BAUSCH HEALTH COMPANIES INC.
NOVO MODERNA INC.
VTRS 10X GENOMICS INC CLASS A
4568.T NOVO NORDISK A/S-B
ME VIATRIS INC.
OCL DAIICHI SANKYO COMPANY
LUND A LIMITED
23ANDME HLDG CO
OAKLEY CAPITAL
H. LUNDBECK A/S

Moody's assigns Baa1 rating to Amgen's new sr. notes; negative outlook

Moody's Investors Service ("Moody's") assigned a Baa1 rating to the new senior unsecured notes offering of Amgen Inc. ("Amgen"). There are no changes to Amgen's existing ratings including the Baa1 senior unsecured rating or the P-2 commercial paper rating, and the outlook is unchanged at negative. ...

Amgen Inc.: Update following confirmation of Baa1 rating and revision ...

Our credit view of this issuer reflects its sizeable revenue base and significant biotechnology presence, constrained by elevated financial leverage following the Horizon acquisition.

Moody's confirms Amgen's Baa1 rating; outlook is negative

Moody's Investors Service ("Moody's") confirmed the Baa1 senior unsecured ratings of Amgen Inc. ("Amgen"). This concludes the rating review for downgrade initiated on December 12, 2022. Amgen's P-2 commercial paper rating, which was not under review for downgrade, remains unchanged at P-2. Following...

Amgen Inc. - September 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc.: Update following ratings under review for downgrade

Our credit view of this issuer reflects its sizeable revenue base and significant biotechnology presence, constrained by its few new molecules in late-stage pipeline.

Moody's places Amgen's Baa1 rating on review for downgrade, affirms P-...

Moody's Investors Service ("Moody's") placed the Baa1 senior unsecured long-term ratings of Amgen Inc. ("Amgen") under review for downgrade. At the same time, Moody's affirmed Amgen's Prime-2 commercial paper rating. Moody's revised Amgen's outlook to ratings under review from stable. These actio...

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Amgen Inc

The Vanguard Group, Inc. ( IRSH) Form 8.3 - The Vanguard Group, Inc.: Amgen Inc 01-Dec-2022 / 14:58 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Ap19   FORM 8.3   IRISH TAKEOVER PANEL   DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013   DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1.  KEY INFORMATION   Name of person dealing (Note 1) The Vanguard Group, Inc. Compa...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch